PROKIDNEY CORP. 8K

ProKidney Corp. announced Q2 2026 results, highlighted key progress in its Phase 3 PROACT 1 trial of rilparencel, appointed a new Chief Technical Officer, and reported $181.6 million in liquidity funding operations into mid-2027 amid continued net losses.

On August 10, 2026, ProKidney Corp. reported its financial results for the second quarter ended June 30, 2026 and provided operational updates, including completion of enrollment for the patient cohort contributing to the accelerated approval efficacy analysis in its Phase 3 REGEN-006 (PROACT 1) trial of rilparencel in advanced chronic kidney disease, confirmation that full enrollment of approximately 470 patients remains on track for the second half of 2026 with key topline readouts expected in Q2 2027 and the second half of 2029, the appointment of Kenneth Locke as Chief Technical Officer to lead technical operations and supply chain as the company prepares for regulatory and commercial milestones, and disclosure that it ended the quarter with $181.6 million in cash, cash equivalents and marketable securities, incurring a net loss before noncontrolling interest of $46.4 million and projecting that existing liquidity will fund operations into mid-2027.

Filing Facts

CIK

1850270

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-342397

Alert Tier

6